Foundation Year:

General Manager:
Marianna Konstantinidi

Number of employees:

14.823.597 €

CSL Behring is a global biotherapeutics company committed to saving lives & improving the quality of life for people with rare & serious diseases worldwide. In case that an unmet or underserved medical need is identified, CSL Behring endeavor to address it – even though the disease is usually rare & the patient population that benefits is very small. The company responds to human needs, not market size.

CSL Behring offers therapies that are used to treat conditions such as: several coagulation disorders including hemophilia A, B & von Willebrand disease, primary & secondary immune deficiencies including Guillain-Barré syndrome, idiopathic thrombocytopenic purpura & Kawasaki disease, hereditary angioedema type I & II, inherited respiratory disease, neurological disorders such as chronic inflammatory demyelinating neuropathy. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment & to prevent hemolytic diseases in the newborn. CSL Behring is a member of the CSL Group of companies. The parent company, CSL Limited (ASX: CSL), is headquartered in Melbourne, Australia. For more information, visit


5, Hatziyianni Mexi str., 11528 Athens

+30 210 7255660,1

+30 210 7255663


[email protected]